Construction of a Two-Gene Immunogenomic-Related Prognostic Signature in Lung Squamous Cell Carcinoma

Xiaoting Zhang1†, Jing Xiao1†, Xian Fu1, Guicheng Qin1, Mengli Yu1, Guihong Chen2* and Xiaofeng Li3*

1Shenzhen Bao’an District Songgang People’s Hospital, Shenzhen, China, 2School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China, 3Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, China

Lung cancer has the highest tumor incidence in China. Lung squamous cell carcinoma (LUSC) is the most common type, accounting for 40–51% of primary lung cancers. LUSC is slow in growth and late in metastasis. Immune-related genes (IRGs) and immune infiltrating cells play a vital role in the clinical outcomes of LUSC. It is important to systematically study its immune gene map to help the prognosis of cancer patients. In this study, we combined the prognostic landscape and expression status of IRGs downloaded from the TCGA and InnatedDB databases and systematically analyzed the prognostic information of LUSC patients to obtain IRGs. After systematically exploring the survival analysis, prognosis-related genes were found, and the PPI network revealed that a total of 11 genes were hub genes. A two-gene prognosis risk model was established by multivariate Cox analysis. Two IRGs were closely correlated with the prognosis of LUSC. Based on these two genes, a new independent prognostic risk model was established, and this model was further verified in the GEO database. Moreover, the risk score of the model was correlated with sex, survival status, and lymphatic metastasis in LUSC patients, and the predictive risk of the prognostic risk model was significantly positively correlated with five kinds of immune cells (CD4 T cells, CD8 T cells, neutrophils, macrophages, and dendritic cells). This study comprehensively analyzed immunogenomics and presented immune-related prognostic biomarkers for LUSC.

Keywords: lung squamous cell carcinoma, immune-related genes, TCGA, prognosis risk model, FGA, CSF2

INTRODUCTION

Lung cancer is one of the most common malignancies worldwide and is caused by malignant cancers (Sung et al., 2021). Lung cancer can be divided into two typical subtypes, small cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and NSCLC, which accounts for approximately 83% of lung cancer patients, is further categorized into lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) according to histological classification and pathogenesis (van Meerbeek et al., 2011). Moreover, LUSC accounts for approximately 30% of NSCLC cases and has an unsatisfactory prognosis due to the lack of effective targeted treatment. NSCLC patients are in
the advanced stage once diagnosed, and their 5-year survival rate is remarkably lower than that of early-stage patients (Tarver 2012; Fujimoto and Wistuba 2014; Wang BY. et al., 2020).

Currently, many treatment modalities, such as surgical resection, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, have been applied to treat lung cancer (Lemjabbar-Alaoui et al., 2015). Surgical resection depends on the advanced stage of cancer. For early-stage NSCLC patients, surgical resection is often the first choice, while for advanced-stage patients whose tumors cannot be removed by surgery, a targeted and more effective therapy depending on molecular tumor characteristics or immunotherapy combined with chemotherapy is more useful (Zarogoulidis et al., 2013). Lung cancer is characterized as a highly complex and heterogeneous disease and several causes are related to lung cancer mortality, such as environmental factors and tobacco smoking habits, which are two major factors in lung cancer (Malhotra et al., 2016; Lipfert and Wyzga 2019). Currently, an increasing number of studies have indicated that some molecular characteristics and signaling pathway targets also contribute to lung cancer development. Abnormal genetic alterations, such as epidermal growth factor receptor (EGFR) (Castellanos et al., 2016; Rodriguezcanales et al., 2016; Liu et al., 2017) and epidermal growth factor receptor 2 (HER2) (Pillai et al., 2014; Catherine et al., 2017), are frequently described to participate in the development of lung cancer.

Thus, to provide a better prognosis suggestion and prediction for patients receiving more precise treatment for LUSC, a predictive prognosis model based on prognostic gene biomarkers is urgently needed. Several clinical information and gene expression datasets can be found in public databases, such as Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA), providing possibilities for bioinformatics analysis in the identification of novel promising biomarkers for cancer treatment. For example, Gao et al. (2020) identified a five-gene-based risk model signature (CCNA2, AURKA, AURKB, and FEN1) to predict the prognosis status of LUSC patients. In addition, the prognostic value of potential immune-related genes (IRGs) was explored to utilize personalized immune signals for optimal prognostic evaluations in nonsquamous NSCLC patients. Although it was reported recently that an 11-gene-related prognostic model, including CXCL5, MMP12, PLAU, ELN, JUN, RNASE7, JAG1, SPP1, AGTR2, FGFR4, and TNFRSF18, performed well in the prognostic forecast in LUSC (Zhang, et al., 2020a), the model was still too complex and inconvenient for clinical diagnosis and practical application. Thus, a simpler and more feasible prognostic risk model that can reveal the prognostic significance and clinical correlation of IRGs in LUSC needs to be further explored.

Accordingly, in this paper, we focused on the prognostic analysis of LUSC patients. We systematically analyzed the clinical information and survival status of LUSC patients downloaded from the TCGA, InnatedDB, and GEO databases to establish a two-gene prognosis risk model for LUSC patients, which also has an excellent ability to predict immune cell infiltration. Our research aimed to provide the potential to provide better treatment advice for LUSC patients.

**MATERIALS AND METHODS**

**Data Collection**

The gene expression dataset and corresponding clinical information for LUSC containing 489 LUSC tissues and 49...
FIGURE 2 | Differentially expressed genes and functional enrichment analysis of differentially expressed IRGs. (A) Volcano plot and heatmap demonstrating differentially expressed genes between lung squamous cell carcinoma (LUSC) and nontumor tissues. Green and red dots represent differentially expressed genes, and gray dots represent genes that were not differentially expressed. (B) Venn diagram shows the common differentially expressed genes and immune-related genes. (C) Significantly enriched KEGG pathways and enriched GO terms based on biological processes. GO = gene ontology, IRGs = immune-related genes, KEGG = Kyoto Encyclopedia of Genes and Genomes.
normal tissues were downloaded from the TCGA database (https://tcga-data.nci.nih.gov/tcga/) (Table 1) (Tomczak et al., 2015). The dataset (accession number: GSE74777) with gene expression information and survival information data, containing a total of 109 tumor samples, was downloaded from the Gene Expression Omnibus (GEO) (https://www.ncbi.nlm.nih.gov/geo/).

**FIGURE 3** | Overall survival-related genes and enrichment analysis. (A) Overall survival curve of ANGPTL3, IL1RL2, FGA, and CSF2. (B) GO enrichment analysis of 46 overall survival-associated genes.
FIGURE 4 | Identification of hub immune-associated genes. (A) Protein-protein interaction network of hub IRGs. (B) Kyoto Encyclopedia of Genes and GO Biological Process analysis of hub IRGs.
A total of 1,697 genes from the InnateDB database (https://www.innatedb.ca) (Bhattacharya et al., 2014) and 1,811 genes from the Immport database (https://www.immport.org) were identified as IRGs. The research procedure is shown in Figure 1.

**Analysis of IRGs in LUSC**

To obtain the differentially expressed genes (DEGs), 489 LUSC tissues and 49 normal tissues shared by the TCGA database were analyzed by the R software limma package, taking a log2 | fold change| > 1 and a false discovery rate (FDR) < 0.01 as screening criteria. The similarity genes in DEGs and 3,187 IRGs searched from the InnateDB and Immport databases were further compared to obtain a series of IRGs in LUSC.

**Survival Analysis**

Multivariate survival analysis in 489 patients with LUSC was performed to investigate the relationship between IRGs and prognosis using the R software survival package. Then, the
prognostic risk model of LUSC was built on the basis of the multivariate coefficient multiplied by expression data. The Kaplan-Meier method and long-rank test, taking the long-rank test and \( p \) value < 0.05 as statistically significant, were used to determine the relationship between overall survival (OS) and survival-related prognostic genes. The property of prognostic factors was computed by the survival ROC by computing the area under the curve (AUC) (Heagerty et al., 2000). Moreover, to investigate the degree of precision of the prognostic risk model in predicting the survival status of LUSC patients, calibration curves and ROC curves were carried out.

**Functional and Pathway Enrichment Analysis**

To further verify whether the IRGs participated in functional regulation and pathways, GO and KEGG enrichment analyses were performed using the R programming language. First, up- and downregulated genes were both analyzed, and a \( p \) value < 0.05 was considered the threshold value. Furthermore, a series of gene functional enrichment analyses, including GO and KEGG analyses, were conducted to identify the major biological attributes. Finally, the GO-plot package was used to generate a bar chart of GO and a circle diagram of KEGG.

**FIGURE 7** | Construction of the prognostic model. (A) Receiver operating characteristic (ROC) curve showing the prognostic value of the risk signature. (B) Patients in the high-risk group demonstrate shorter overall survival. (C) Survival conditions of LUSC patients.
Transcription Factor-mRNA Interaction Analysis

The regulatory relationship between transcription factors and mRNAs was downloaded from the TRRUST v2 database (www.grnpedia.org/trrust) (Mei et al., 2017). Those transcription factors that interacted with hub genes were selected to construct the interaction network to establish a correlation between IRGs and TFs, which was further exhibited by Cytoscape.

Recognition of Hub Genes and Verification of Their Molecular Characteristics

The IRGs were analyzed with the STRING database (https://string-db.org/) to establish a protein–protein network and further reorganized by Cytoscape software. Related hub genes were found according to the node degree in the network, and the mutation information of those hub genes was obtained based on the Cbioportal website (http://www.cbioportal.org/) (Cerami et al., 2012; Gao et al., 2013).

Establishment and Verification of the Prognostic Risk Model

A multivariate Cox proportional hazards regression analysis was performed using the candidate prognostic genes to build a risk prognostic risk model. Furthermore, the median value of 107 cancer samples from the accession set GSE74777 in the GEO database, which was utilized as the training dataset, was calculated separately to evaluate the prediction accuracy of the prognostic risk model. P < 0.05 was considered significant.

The Relationship Between the Prognostic Predictive Model and Other Clinical Characteristics

The infiltration status of six kinds of immune-related cells from cancer tissues was calculated on the TIMER website (https://cistrome.shinyaoos.io/timer/). T tests and Kruskal–Wallis tests were performed to identify the relationship between the prognostic predictive model and other infiltration clinical factors separately. P < 0.05 indicates statistical significance.

RESULTS

Identification of Differentially Expressed Immune-Related Genes

The number of IRGs was found to be 3,187 by taking the union of genes downloaded from the InnateDB and Immport datasets, which were 1,697 and 1811, respectively.

There were 1,697 IRGs downloaded from the InnateDB database (https://www.innatedb.ca/) and 1811 IRGs downloaded from the Immport database (https://www.immport.org). We combined the two results and found a total of 3,187 IRGs. A total of 6,152 DEGs were screened after screening the gene expression data of 489 LUSC tissues and 49 normal tissues by taking log2 | fold change|>1 and false discovery rate (FDR) < 0.01. When comparing the gene expression levels in the normal tissues, 4,102 genes were upregulated, and 2050 genes were downregulated (Figure 2A).

Combining 6,152 differentially expressed genes with 3,187 IRGs, the 384 genes in the intersection were considered LUSC IRGs (Figure 2B). Functional and pathway enrichment analysis of the 384 IRGs revealed their role in a biological network related to innate immune regulation and humoral immune reaction regulation (Figure 2C).

Identification of Prognosis-Related Genes

To select genes related to the prognosis of LUSC, 384 IRGs were divided into high-expression and low-expression groups according to the median expression level (Supplementary Table S1). After performing a survival analysis, 46 survival-related prognostic genes were found (Supplementary Table S2). Some of the gene survival curves are shown in Figure 3A. Furthermore, functional and pathway enrichment analyses were carried out and revealed that these genes were involved in cell factor regulation and cell maturation regulation (Figure 3B).

Construction of the PPI Network and Identification of Hub IRGs

We placed forty-six prognostic IRGs into the STRING database to investigate their value in the protein–protein interaction network, and we reconstructed them with Cytoscape software. The PPI network showed that it contained 32° and 53 sides. A total of 11 hub IRGs were identified by calculating the degree of every prognostic IRG and taking degree>3 (Figure 4A). Functional and pathway enrichment analyses were performed and indicated that the hub IRGs were involved in cell factor-receptor interactions and the tumor necrosis signaling pathway (Figure 4B).

The expression signature of hub IRGs and the HR forest graph showed that most of those hub IRGs were upregulated and were risk factors (Figures 5A,B). Furthermore, we obtained their genetic mutation information from the Cbioportal website to explore their biological molecular characteristics. We found that amplification and mRNA upregulation were the two most common mutation types (Figure 5C).

Transcription Factor Regulatory Network

We screened human TF-mRNA regulation from the TRRUST v2 database and showed that many transcription factors interacted with hub IRGs, including MYB, SP1, and SP3 (Figure 6).

Construction of a Prognostic Risk Based on Hub IRGs

A multivariate Cox analysis was performed to explore the associations between the hub IRGs and the predicitve signature, and two key genes (FGA and CSF2) were finally used as independent prognostic factors in establishing the prognostic risk model of LUSC patients. The prognostic risk model of LUSC based on two independent genes was as follows: Risk Score = EXPFGA*0.1340112 + EXPCSF2*0.2431801.
The AUC value of the prognostic risk model was 0.61 when predicting LUSC patient samples at 1 year, indicating that the expression of FGA and CSF2 could predict the prognosis status of LUSC patients (Figure 7A). We calculated the prognostic risk value of individual patients and classified them into high-risk and low-risk groups on the basis of their expected risk value in the prognostic risk model, which showed that there was a remarkable difference between the two groups (Figures 7B,C).

Verification of the Prognostic Risk Model
To further validate the predictive ability of the prognostic risk model of LUSC, the GSE74777 dataset, including 107 cancer samples from the GEO database, was collected. The AUC (OS) and AUC (PFS) values of each sample were calculated, and the predictive values of the prognostic risk model at 1 year were 0.52 and 0.65, respectively (Figures 8A, C). In addition, we calculated the risk value of every patient and categorized them into high-risk and low-risk groups based on their risk value in the prognostic risk model, which showed that it was significant in both groups (Figures 8B,D) (p < 0.05).

Clinical Utility of the Prognostic Signature
We applied T test and Kruskal–Wallis analyses to evaluate the relationship between the prognostic risk model of LUSC and clinical characteristics (age, sex, clinical stage, and metastasis). The statistical tests showed that the patients with LUSC, age, distant metastasis stage T, and M had no significant correlation with the prognostic prediction, while the recurrence risk in different T stages had a relationship with extent (p = 0.059/ p = 0.055) (Figures 9A–E). However, the prognostic risk was significantly associated with lymph node metastasis N (Figure 9F) (p < 0.05).

Immunocyte Infiltration in the LUSC Microenvironment
We calculated the infiltration signature of six kinds of immune-related cells on the Timer website and evaluated the correlation between the predictive risk of the prognostic risk model of LUSC and the infiltration of those cells. The predictive risk of the prognostic risk model was significantly positively correlated.
with five kinds of immune cells except for B cells (Figure 10C) (CD4 T cells (Figure 10A), CD8 T cells (Figure 10B), neutrophils (Figure 10D), macrophages (Figure 10E), and dendritic cells (Figure 10F). Interestingly, the infiltration status increased when the predictive risk of the prognostic risk model was high.

**DISCUSSION**

Lung cancer is heterogeneous and has no effective treatment options when it progresses to the late stage (Leitao et al., 2018). The genomic mutation patterns in LUSC are complex (de Sousa...
and Carvalho 2018). Mutations in ALK and EGFR have caused huge changes in the treatment of patients with lung adenocarcinoma (Lynch et al., 2004; Paez et al., 2004; Soda et al., 2007). However, ALK fusions or EGFR mutations do not exist in LUSC (Rekhtman et al., 2012). Thus, a novel LUSC biomarker with high specificity and high sensitivity needs to be identified for clinical diagnosis and prognosis.

Recently, the importance of IRGs in many cancer immunotherapies has been accepted and is on the rise (Campbell et al., 2016; Faruki et al., 2017). However, an overall genome-wide analysis of LUSC is still needed to explore the clinical significance and even the molecular mechanism. In this study, we showed the effects of IRGs on LUSC clinical significance and explained the molecular features. These IRGs are potentially valuable for clinical characteristics.

To construct a simple and suitable formula to predict the clinical outcomes of LUSC patients, two IRGs (FGA and CSF2) were selected from 11 hub IRGs to establish the risk signature (risk score = EXPFGA*0.1340112 + EXPCSF2*0.2431801). LUSC patients with high-risk values have a poor prognosis, and this risk signature has the ability to distinguish high-risk LUSC patients. Moreover, this signature may be applied as an independent prognostic factor.

FGA encodes the subunit of the coagulation factor fibrinogen, which is a component of the blood clot (Simpson-Haidaris and Rybarczyk 2001; Staton et al., 2003). Mutation of FGA can result in hereditary systemic amyloidosis (Benson, 2005). It was reported that FGA and related fragments are involved in tumor angiogenesis and metastasis. FGA and its catabolite can regulate the overall antigenicity of solid tumors (Wang M. et al., 2020). Importantly, FGA can interact with HBsAg and induce apoptosis in HepG2 cells (Li et al., 2014). It has been reported that FGA inhibits cell proliferation and migration and induces apoptosis in A549 cells. Wang et al. (2020) recently found that knockout of fibrinogen alpha increased tumor growth and metastasis by activating the integrin-AKT signaling pathway in lung cancer. Furthermore, the FGA isoform has been shown to be a predictor of targeted therapy in patients with EGFR-mutated lung adenocarcinoma (Shang et al., 2019). Colony

![FIGURE 10](https://example.com/figure10.png)

**FIGURE 10** | Relationships between the immune-related prognostic index and immune cell infiltration. (A) CD4 T cells; (B) CD8 T cells; (C) B cells; (D) dendritic cells; (E) macrophages; (F) neutrophils.
CD8+ T-cell response to PD-1-targeted therapy is correlated with Interestingly, it has been reported that the early proliferative macrophages, and neutrophils. These resistance. Tumor-associated macrophage in a favorable prognosis in NSCLC patients. Tumor-associated needed for this signature, which might be valuable for the reliable validation with large-scale sample cohorts is still predictor of immune status in patients with LUSC. Further score = EXPFGA*0.1340112 + EXPCSF2*0.2431801) could be associated with tumor cell proliferation and survival in patients with LUSC.

Overall, our findings reported that the novel signature (risk score = EXPFGA*0.1340112 + EXPCSF2*0.2431801) could be applied as a prognostic method for LUSC and a potential predictor of immune status in patients with LUSC. Further reliable validation with large-scale sample cohorts is still needed for this signature, which might be valuable for the clinical diagnosis of LUSC in the future.

**REFERENCES**

Benson, M. D. (2005). Ostertag Revisited: the Inherited Systemic Amyloidoses without Neuropathy. *Amyloid* 12, 75–87. doi:10.1080/1350560050106925

Beug, S. T., Cheung, H. H., Sanda, T., St-Jean, M., Beauregard, C. E., Mamady, H., et al. (2019). The Transcription Factor SP3 Drives TNF-α Expression in Response to 5mac Mimetics. *Sci. Signal.* 12, eaat9563. doi:10.1126/scisignal.aat9563

Bhattacharya, S., Andorf, S., Gomes, L., Dunn, P., Schaefer, H., Pontius, J., et al. (2014). ImmPort: Disseminating Data to the Public for the Future of Immunology. *Immunol. Res.* 58, 234–239. doi:10.1007/s12026-014-8516-1

Campbell, J. D., Alexandrov, A., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., et al. (2016). Distinct Patterns of Somatic Genome Alterations in Lung Adenocarcinomas and Squamous Cell Carcinomas. *Nat. Genet.* 48, 607–616. doi:10.1038/ng.3564

Castellanos, E., Feld, E., and Horn, L. (2016). Driven by Mutations: The Predictive Value of Mutation Type in EGFR-Mutated Non-small Cell Lung Cancer. *J. Thorac. Oncol.* 12, 612–623. doi:10.1016/j.jtho.2016.12.014

Catherine, L., Cabanero, M., Grzegorz, J., Korpanty, P., and Tomasini, M. (2017). Prognostic and Predictive Effects of TP53 Co-mutation in Patients with EGFR-Mutated Non-small Cell Lung Cancer (NSCLC) - ScienceDirect. *Lung Cancer* 111, 23–29. doi:10.1016/j.lungcan.2017.06.014

Cerami, E., Gao, J., Dogrusoz, U., Gross, R. E., Sumer, S. O., Aksoy, B. A., et al. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1. Cancer Discov. 2, 401–404. doi:10.1158/2159-8290.cd-12-0095

de Sousa, V. M. L., and Carvalho, L. (2018). Heterogeneity in Lung Cancer. *Pathobiology* 85, 96–107. doi:10.1159/000487440

Faruki, H., Mayhew, G. M., Serody, J. S., Hayes, D. N., Perou, C. M., and Lai-Goldman, M. (2017). Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. *J. Thorac. Oncol.* 12, 943–953. doi:10.1016/j.jtho.2017.03.010

Fujimoto, J., and Wistuba, II (2014). Current Concepts on the Molecular Pathology of Non-small Cell Lung Carcinoma. *Semin. Diagn. Pathol.* 31, 306–313. doi:10.1053/j.semdp.2014.06.008

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

XZ and XL conceived of the idea and wrote the manuscript. XF, MY, JX and GQ prepared the data and analyzed the results. XL and GC supervised this work.

**FUNDING**

The study was supported by the Shenzhen Project of Science and Technology (Grant No. JCYJ20180302145109198 to Z.X.T, Grant No. JCYJ20210324123012034 to Z.X.T and JCYJ20190809094407602 to L.X.F), the National Natural Science Foundation of China (81801517 to L.X.F), the Scientific Research Foundation of Peking University Shenzhen Hospital (KYQD2021104) and the fund of the “San-ming” Project of Medicine in Shenzhen (No. SZSM201812088).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2022.867494/full#supplementary-material
Response to Gefitinib Therapy. Science 304, 1497–1500. doi:10.1126/science.1099314

Pillai, R. N., Behena, M., Berry, L. D., Rossi, M. R., Kris, M. G., Bunn, P. A., et al. (2014). HER2 Mutations in Lung Adenocarcinoma: A Report from the Lung Cancer Mutation Consortium (LCMC). Jco 32, 8060. doi:10.1200/jco.2014.32.15_suppl.8060

Rekhtman, N., Paik, P. K., Arcila, M. E., Tafe, I. J., Oxnard, G. R., Moreira, A. L., et al. (2012). Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations. Clin. Cancer Res. 18, 1167–1176. doi:10.1158/1078-0432.ccr-11-2109

Rodriguez-Canales, J., Parra-Cuentas, E., and Wistuba, II (2016). Diagnosis and Molecular Classification of Lung Cancer. Cancer Treat. Res. 170, 25–46. doi:10.1007/978-3-319-30839-2_2

Shang, Z., Niu, X., Zhang, K., Qiao, Z., Liu, S., Jiang, X., et al. (2019). FDA Isosform as an Indicator of Targeted Therapy for EGFR Mutated Lung Adenocarcinoma. J. Mol. Med. 97, 1657–1668. doi:10.1007/s00109-018-1084-z

Sielska, M., Przanowski, P., Pasierbińska, W., Wojnicki, K., Poleszak, K., Wojtas, B., et al. (2020). Tumor-derived CSF2/granulocyte Macrophage colony Stimulating Factor Controls Myeloid Cell Accumulation and Progression of Gliomas. Br. J. Cancer 123, 438–448. doi:10.1038/s41416-020-0862-z

Simpson-Had经历过, P. J., and Rybarczyk, B. (2001). Tumors and Fibrogenesis. The Role of Fibrinogen as an Extracellular Matrix Protein. Ann. N. Y Acad. Sci. 936, 406–425. doi:10.1111/j.1749-6632.2001.tb03525.x

Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007). Identification of the Transforming EML4-ALK Fusion Gene in Non-small-cell Lung Cancer. Nature 448, 561–566. doi:10.1038/nature05945

Sousa, L. D., Vitor, M., and Carvalho, L. (2018). Heterogeneity in Lung Cancer. Pathobiology. Immunopathology Mol. Cell Biol. 85, 96–107. doi:10.1159/000478440

Staton, C. A., Brown, J. N., and Lewis, C. E. (2003). The Role of Fibrinogen and Related Fragments in Tumour Angiogenesis and Metastasis. Expert Opin. Biol. Ther. 3, 1105–1120. doi:10.1517/14712598.3.7.1105

Sung, H., Fierav, J., Siegl, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A. Cancer J. Clin. 71, 209–249. doi:10.3322/caac.21660

Tarver, T. (2012). Cancer Facts & Figures 2012. American Cancer Society (ACS). J. Consumer Health Internet 16, 366–367. doi:10.1053/j.ajcp.2012.07.0117

Tomczak, K., Czerwińska, P., and Wiznerowicz, M. (2015). The Cancer Genome Atlas (TCGA): An Immeasurable Source of Knowledge. Contemp. Oncol. (Poln) 19, 468–477. doi:10.5114/co.2014.47136

van Meerbeck, J. P., Fennell, D. A., and De Ruysscher, D. K. (2011). Small-cell Lung Cancer. The Lancet 378, 1741–1755. doi:10.1016/s0140-6736(11)60165-7

Wang, B. Y., Huang, J. Y., Chen, H. C., Lin, C. H., Lin, S. H., Hung, W. H., et al. (2020a). The Comparison between Adenocarcinoma and Squamous Cell Carcinoma in Lung Cancer Patients. J. Cancer Res. Clin. Oncol. 146, 43–52. doi:10.1007/s00432-019-03079-8

Wang, M., Zhang, G., Zhang, Y., Cui, X., Wang, S., Gao, S., et al. (2020b). Fibrinogen Alpha Chain Knockout Promotes Tumor Growth and Metastasis through Integrin-AKT Signaling Pathway in Lung Cancer. Mol. Cancer Res. 18, 943–954. doi:10.1158/1541-7786.MCR-19-1033

Yu, Y., Cao, F., Xiong, Y., and Zhou, H. (2021). SPI Transcriptionally Activates Fibrinogen Alpha Chain in Lung Cancer Patients. J. Mol. Med. 97, 1657–1668. doi:10.1007/s00109-018-1084-z

Zarogoulidis, K., Zarogoulidis, P., Darwiche, K., Boutsikou, E., Machairiotis, N., Varkarakis, M., et al. (2013). Treatment of Non-small Cell Lung Cancer with Erlotinib and Cetuximab Resistance in Colorectal Cancer. Oncotarget 3, 1105–1120. doi:10.1517/14712598.3.7.1105

Zhang, J., Zhang, J., Yuan, C., Luo, Y., Li, Y., Dai, P., et al. (2020a). Establishment of the Prognostic index of Lung Squamous Cell Carcinoma Based on Immunoscore CA A. Cancer J. Clin. 71, 96–107. doi:10.1007/s00432-019-03079-8

Zarogoulidis, K., Zarogoulidis, P., Darwiche, K., Boutsikou, E., Machairiotis, N., Varkarakis, M., et al. (2013). Treatment of Non-small Cell Lung Cancer (NSCLC). J. Thorac. Dis. 5 Suppl 4 (Suppl. 4), S389–S396. doi:10.3324/jtd.2012-1439.2013.07.10

Zhang, J., Zhang, J., Yuan, C., Luo, Y., Li, Y., Dai, P., et al. (2020a). Establishment of the Prognostic index of Lung Squamous Cell Carcinoma Based on Immunoscore CA A. Cancer J. Clin. 71, 96–107. doi:10.1007/s00432-019-03079-8
Zhang, X., Quan, F., Xu, J., Xiao, Y., Li, X., and Li, Y. (2020b). Combination of Multiple Tumor-Infiltrating Immune Cells Predicts Clinical Outcome in colon Cancer. *Clin. Immunol.* 215, 108412. doi:10.1016/j.clim.2020.108412

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Xiao, Fu, Qin, Yu, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.